Adagene (ADAG) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Yarrow Bioscience (YARW) over the past year, gaining 42.2% versus a loss of 7.6%. Over five years, ADAG leads with a -76.2% price change compared with -98.2% for YARW. Yarrow Bioscience is the larger company by market cap ($189.9 million vs $179.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | YARW |
|---|---|---|
| Share price | $2.67 | $20.41 |
| Market cap | $179.27M | $189.90M |
| 1-day change | -3.96% | +2.72% |
| YTD return | +47.09% | -31.48% |
| 1-year return | +42.20% | -7.58% |
| 5-year return | -76.24% | -98.19% |
| EPS (TTM) | $-0.37 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $46.95 |
| 52-week low | $1.30 | $16.05 |
| Distance from 52-week high | -44.95% | -56.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +271.16% | +179.27% |
| Average volume | 244.76K | 88.98K |
| Shares outstanding | 67.14M | 9.30M |
| Employees | 128 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed YARW by 49.8 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ADAG vs YARW FAQ
Which is bigger, Adagene or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $189.90M compared with $179.27M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or YARW?
ADAG returned +42.20% over the past 12 months, compared with -7.58% for YARW (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.